Added to YB: 2025-11-27
Pitch date: 2025-11-25
CAPR [bearish]
Capricor Therapeutics, Inc.
-458.37%
current return
Author Info
AnthonyStaj shares thoughts and musings on biotech, mostly. L/S, not afraid of indication, highly focused on clinical and commercial analysis. Sign up for the newsletter.
Company Info
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Market Cap
$212.1M
Pitch Price
$4.66
Price Target
2.00 (-92%)
Dividend
N/A
EV/EBITDA
-1.56
P/E
-2.57
EV/Sales
11.51
Sector
Biotechnology
Category
special_situation
Star sign Capricor: when astrology does drug development
CAPR (short): 15-year cell therapy failure across 8+ indications; mechanism lacks biological plausibility (1% heart uptake, 7-min exosome half-life); HOPE-2 baseline imbalances confounded results; 31% grade 3-4 anaphylaxis rates; FDA CRL citing lack of efficacy, manufacturing issues. HOPE-3 readout imminent, targeting $2 cash value vs $5.80 current price.
Read full article (29 min)